Jefferies Starts Eli Lilly (LLY) at Hold, 'Priced to Perfection'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. LMT
9. SPY
10. SBUX

Go back to Jefferies Starts Eli Lilly (LLY) at Hold, 'Priced to Perfection'

U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer

March 3, 2023 2:58 PM EST

High risk patients eligible for Verzenio can now be identified solely based on nodal status, tumor size, and tumor grade, regardless of Ki-67 score

Approval supported by four-year data from the monarchE trial; Verzenio added to adjuvant endocrine therapy (ET) reduced the risk of recurrence by 35% compared to adjuvant ET alone  

Verzenio remains the first and only CDK4/6 inhibitor approved in the adjuvant setting

INDIANAPOLIS, March 3,... More